Sanjeev Kumar

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 9 CIPO patents and 12 EPO patents. Top assignees: Newlink Genetics Corporation, Genentech, Inc., Lankeanau Institute for Medical Research. Active years: 2014-2026.

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 60.0

CIPO Patents = 9 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 11)

Average Co-Inventor Count = 6.2

ph-index = 4

Forward Citations = 45(Granted Patents)

Company Filing History:

14 out of 22

Newlink Genetics Corporation

Lankeanau Institute for Medical Research

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583858 - TDO2 inhibitors (2026-03-24),

2. 11827639 - TDO2 and IDO1 inhibitors (2023-11-28),

3. 11485705 - Salts and prodrugs of 1-methyl-d-tryptophan (2022-11-01),

4. 10800780 - TDO2 Inhibitors (2020-10-13),

5. 10233190 - IDO inhibitors (2019-03-19),

6. 10207990 - Salts and prodrugs of 1-methyl-D-tryptophan (2019-02-19),

7. 9981973 - Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization (2018-05-29),

8. 9850248 - IDO inhibitors (2017-12-26),

9. 9732035 - Salts and prodrugs of 1-methyl-D-tryptophan (2017-08-15),

10. 9617272 - Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization (2017-04-11),

11. 9388191 - Fused imidazole derivatives useful as IDO inhibitors (2016-07-12),

12. 9260434 - Fused imidazole derivatives useful as IDO inhibitors (2016-02-16),

13. 9174942 - IDO inhibitors (2015-11-03),

14. 8748469 - IDO inhibitors (2014-06-10),

15. 8722720 - Imidazole derivatives as IDO inhibitors (2014-05-13),

Title: **The Innovative Mind of Sanjeev Kumar: Pioneering Immunotherapy**

Introduction

Sanjeev Kumar, an influential inventor located in Ames, IA, has made significant contributions to the field of immunotherapy with a diverse portfolio of 14 patents. His groundbreaking work focuses primarily on the modulation of tryptophan metabolism, which plays a crucial role in cancer treatment and immunosuppression.

Latest Patents

Among his latest innovations are patents related to TDO2 and IDO1 inhibitors, which provide pharmaceutical compositions capable of modulating the activity of tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1. These inhibitors are instrumental in treating immunosuppression and enhancing the effectiveness of anti-cancer therapies. Additionally, Kumar has developed salts and prodrugs of 1-methyl-d-tryptophan, particularly focusing on indoximod prodrug and salt compounds. These compositions significantly increase plasma concentration and exposure to indoximod, making them vital for treating patients suffering from cancer or chronic infectious diseases.

Career Highlights

Sanjeev Kumar has worked with renowned companies in the biopharmaceutical industry, including NewLink Genetics Corporation and Genentech, Inc. His impressive knowledge and expertise have allowed him to remain at the forefront of innovation, particularly in the realm of immunotherapy.

Collaborations

Throughout his career, Kumar has collaborated with notable professionals such as Firoz Jaipuri and Jesse Waldo. These partnerships reflect his commitment to advancing cancer treatment and improving patient outcomes through innovative research and development.

Conclusion

Sanjeev Kumar exemplifies the spirit of innovation in the medical field. His contributions, particularly with his latest patents in immunotherapy, demonstrate his unwavering dedication to tackling complex medical challenges. As he continues to develop novel therapeutic solutions, Kumar's work remains pivotal in the ongoing fight against cancer and immunosuppressive conditions.